TetraLogic Pharmaceuticals tetralogicpharma.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

TetraLogic Pharmaceuticals is focused on the discovery and development of drugs to treat cancer through technology which allows drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells. TetraLogic's lead Smac mimetic drug, birinapant (formerly TL32711), is entering Phase 2 clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapi...Show all

TetraLogic Pharmaceuticals is focused on the discovery and development of drugs to treat cancer through technology which allows drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells. TetraLogic'...Show all

Company (IPO / Went public)

Phone: 610-889-9900

Fax:

343 Phoenixville Pike

Malvern, 19355
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
TetraLogic Pharmaceuticals $165.1M Dec 12, 2013
See all 21 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related TetraLogic Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
HealthCare VenturesVenture CapitalCambridge, Massachusetts, United StatesDebt, Series C - III, Series C - II, Series C, Series B, Series A
ClarusVenture CapitalCambridge, Massachusetts, United StatesDebt, Series C - III, Series C - II, Series C
Amgen VenturesCorporate VentureThousand Oaks, California, United StatesSeries C - II, Series C, Series B
Hatteras Venture PartnersVenture CapitalDurham, North Carolina, United StatesDebt, Series C - III, Series C - II, Series C
Kammerer AssociatesSeries B
See all 12 investors

Competitors

Company Status Description Investors
See all 21 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Iap binding compounds Jul 16, 2014 Jul 19, 2016 Patent
Dimeric iap inhibitors Jul 21, 2014 Nov 17, 2015 Patent
Smac mimetic for treating myelodysplastic syndromes Nov 08, 2013 Mar 24, 2015 Patent
Dimeric iap inhibitors Jun 25, 2013 Sep 02, 2014 Patent
Iap binding compounds Jun 25, 2013 Aug 12, 2014 Patent
See all 20 patents